Clinical Trials for Small Cell Lung Cancer

PRISM: Phase 1b of Retifanlimab and Ruxolitinib In Solid Malignancies Progressing on Prior Checkpoint Inhibition

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with advanced/metastatic clear cell renal cell carcinoma or non-small cell lung cancer who had at least stable disease on one prior line of PD-1/PD-L1 therapy but then radiographically progressed within 6 months of stopping it (ECOG 0–1; measurable disease; no active CNS disease or uncontrolled autoimmune disease) and lack/decline standard options. Patients receive retifanlimab (anti–PD-1 antibody) 500 mg IV every 4 weeks as checkpoint rechallenge combined with oral ruxolitinib (JAK1/2 inhibitor) twice daily with dose escalation to define the recommended dose.

ClinicalTrials.gov ID: NCT07219576

PRIME-LRT: PRomoting IMmunotherapy Efficacy With Low-Dose Liver RT

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolls adults with biopsy-proven NSCLC (excluding EGFR/ALK/ROS1/RET-altered tumors) or melanoma with radiographic liver metastases, ECOG 0–2, eligible for standard PD-1/PD-L1 checkpoint inhibitor–based therapy (± chemotherapy and/or CTLA-4 inhibition per routine practice). All patients receive standard systemic therapy plus investigational low-dose liver radiation delivered in the week before cycles 1, 2, and 3 to potentially modulate the hepatic immune microenvironment and enhance checkpoint inhibitor efficacy.

ClinicalTrials.gov ID: NCT07225036

Consolidative Use of Radiotherapy to Block (CURB2) Oligoprogression In Patients With Metastatic Non-Small-Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with stage IV NSCLC without actionable driver mutations (ECOG 0–2) who develop oligoprogression (≤5 lesions, all safely treatable with SBRT/ablative RT) after ≥3 cycles of first-line immune checkpoint inhibitor–based therapy (ICI alone or ICI+chemotherapy; stable treated CNS metastases allowed). Compares SBRT/ablative radiotherapy to all progressing sites with continuation of current standard systemic management versus no RT and switching to standard approved second-line systemic therapy.

ClinicalTrials.gov ID: NCT06686771

IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with advanced/metastatic non-squamous NSCLC harboring sensitizing EGFR exon 19 deletion or L858R mutations with documented progression after a third-generation EGFR TKI regimen and eligible for platinum doublet chemotherapy. Patients are randomized to investigational izalontamab brengitecan (BMS-986507; targeted anticancer biologic with target/payload not publicly characterized, dose/schedule being optimized) versus cisplatin or carboplatin plus pemetrexed.

ClinicalTrials.gov ID: NCT07100080

A Phase 1/2 Study of REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable or metastatic MET-altered NSCLC and ECOG performance status 0–1 receive investigational davutamig (REGN5093) monotherapy. This biparatopic antibody binds MET at two sites, blocks ligand binding, and promotes receptor internalization and degradation.

ClinicalTrials.gov ID: NCT04077099

Assessing the Impact of Circadian Rhythm on Anti-PD-1/PD-L1 Immunotherapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with advanced/metastatic cancers—especially first-line NSCLC (including maintenance after induction) and other solid tumors—who are receiving FDA on-label PD-1/PD-L1 immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab, atezolizumab, durvalumab; agents that block PD-1/PD-L1 signaling to restore T-cell antitumor activity) alone or with other approved therapies. Patients are randomized to receive each ICI dose on an early schedule (completed by 11:00 AM) versus a late schedule (start after 12:00 PM) to assess differences in outcomes and toxicity.

ClinicalTrials.gov ID: NCT07224971

A Double-Blind Phase II Randomized Study of Adaptively Delivered LINAC-Based Stereotactic Radiation for Volatile Brain Metastases With Same-Day Planning and Margin Reduction

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults (≥18) with solid tumors and at least one intact/residual/recurrent “volatile” brain metastasis at higher risk for interval change/displacement (e.g., rapid growth, near edema or recent surgical cavity), KPS ≥60 and expected survival ≥3–6 months, are treated with same-day MRI-simulated, adaptively planned LINAC-based stereotactic radiosurgery/radiotherapy. Patients are randomized to stereotactic radiation using a 0 mm versus 1 mm planning target volume margin to test whether tighter margins can maintain control while reducing geographic miss and toxicity (e.g., radiation necrosis).

ClinicalTrials.gov ID: NCT07132190

A Phase 2 Study to Investigate the Safety and Efficacy of Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer in Combination With Pembrolizumab as First-Line Treatment

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Eligible patients are adults with previously untreated stage IV squamous or non-squamous NSCLC with PD-L1 TPS ≥50%, ECOG 0–1, measurable disease, and (for non-squamous) no actionable genomic alterations, excluding untreated CNS metastases and prior PD-(L)1 therapy. Treatment is petosemtamab (investigational EGFR×LGR5 bispecific antibody intended to inhibit tumor signaling and enhance immune-mediated activity) plus pembrolizumab (PD-1 inhibitor) as first-line therapy.

ClinicalTrials.gov ID: NCT07353957

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination With Pembrolizumab and Chemotherapy as First-Line Treatment for Participants With Metastatic Squamous NSCLC (INTerpath-013)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously untreated stage IV squamous NSCLC and ECOG performance status 0–1 are randomized to pembrolizumab plus carboplatin and paclitaxel or nab-paclitaxel, with either V940 or placebo. V940 is a patient-specific mRNA therapy encoding tumor neoantigens to stimulate tumor-directed T cells.

ClinicalTrials.gov ID: NCT07221474

Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with extensive-stage (or locally advanced non-curable) small cell lung cancer who have completed 4–6 cycles of first-line platinum/etoposide plus atezolizumab or durvalumab and have CR/PR/SD without progression (ECOG 0–2; stable asymptomatic brain metastases allowed) receive maintenance sacituzumab govitecan, a TROP-2–directed antibody–drug conjugate delivering SN-38, combined with ongoing PD-L1 inhibitor maintenance (atezolizumab or durvalumab) until progression/toxicity (up to 2 years).

ClinicalTrials.gov ID: NCT07339059